文献速递胸部肿瘤放疗放疗物理与技术

局部晚期非小细胞肺癌的平行探索:考虑免疫治疗与心脏毒性保护的放化疗剂量-效应优化

Parallel explorations in LA-NSCLC: Chemoradiation dose-response optimisation considering immunotherapy and cardiac toxicity sparing.
PubMed 文献 · Radiother Oncol · 2024-08-15

本研究基于已发表研究的生存数据与剂量学指标,采用最大似然拟合的放化疗剂量-效应模型,并加入免疫检查点阻断与心脏保护假设进行修正。模型预测同步放化疗联合免疫检查点阻断在60 Gy分30次时2年总生存率IIIA期为71%、IIIB/C期为66%,心脏保护可使2年总生存率提高5-10%,质子治疗可再提高约5-10%。

要点

  • 同步放化疗联合免疫检查点阻断时,60 Gy分30次仍是最佳方案,剂量降至55 Gy仅使总生存率降低2%。
  • 光子心脏保护使模型2年总生存率提高5-10%,质子治疗可在此基础上再提高约5-10%。
  • 序贯放化疗联合免疫检查点阻断较序贯放化疗单独最佳总生存率提高6%。

核心结论

  • 相对于60 Gy分30次,剂量递增或递减均未影响同步放化疗联合免疫检查点阻断的生存,而5 Gy剂量递减可能使受照危及器官较重的患者获益。
  • 心脏保护改善了总生存率,质子治疗为解剖上与心脏重叠或位于心脏下方的肿瘤提供了优势。

研究设计与样本

  • 生存数据与剂量学指标来源于已发表研究,对2年总生存率进行标准化,并整理平均心脏剂量与放射毒性的风险比为表格。
  • 选用已发表的放化疗剂量-效应模型,并以免疫检查点阻断与心脏保护假设进行修正,模型经最大似然拟合后通过自举法可视化预测结果。

主要发现

  • 在60 Gy分2 Gy/次条件下,模型预测同步放化疗联合免疫检查点阻断的2年总生存率IIIA期为71%(95%CI 62%,84%),IIIB/C期为66%(95%CI 53%,81%)。
  • 60 Gy分30次仍是同步放化疗联合免疫检查点阻断的最佳方案,而适度剂量递减至55 Gy仅使总生存率降低2%。
  • 序贯放化疗联合免疫检查点阻断较序贯放化疗单独达到的最佳总生存率提高6%。
  • 光子平均心脏剂量保护使模型2年总生存率提高5-10%,质子治疗进一步提供约5-10%的提高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Chemoradiotherapy (CRT) for locally-advanced non-small cell lung cancer (LA-NSCLC) has undergone advances, including increased overall survival (OS) when combined with immune checkpoint blockade (ICB), and using cardiac-sparing techniques to reduce the radiotoxicity. This research investigated 1) how radiotherapy schedules can be optimised with CRT-ICB schemes, and 2) how cardiac-sparing might change the OS for concurrent CRT (cCRT). METHODS AND MATERIALS: Survival data and dosimetric indices were sourced from published studies, with 2-year OS standardised and the hazard ratio of mean heart dose (MHD) against radiotoxicity tabulated in purpose. A published CRT dose-response model was selected, then modified with ICB and cardiac-sparing hypotheses. Models were maximum likelihood fitted, then visualised the prediction outcomes after bootstrapping. RESULTS: The modelled 2-year OS rate of cCRT-ICB reached 71 % (95 % confidence intervals, CI 62 %, 84 %) and 66 % (95 % CI: 53 %, 81 %) for stage IIIA and IIIB/C, respectively, given 60 Gy in 2 Gy-per-fraction. 60 Gy in 30 fractions remained the best schedule for cCRT-ICB, whereas modest dose de-escalation to 55 Gy only reduced the OS in 2 %. Sequential CRT (sCRT)-ICB provided 6 % OS increases versus the best OS rate achieved by sCRT alone. Photon MHD-sparing achieved a 5-10 % increase in modelled 2-year OS, with protons providing a further roughly 5-10 % increase. CONCLUSION: Neither dose-escalation nor de-escalation relative to 60 Gy in 30 fractions influenced the survival with cCRT-ICB, while 5 Gy dose de-escalation might benefit patients with heavily irradiated organs at risk. Cardiac-sparing improved OS, and protons provided advantages for tumours anatomically overlapped or lay below the heart.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Huang HT. Parallel explorations in LA-NSCLC: Chemoradiation dose-response optimisation considering immunotherapy and cardiac toxicity sparing. Radiother Oncol. 2024. PMID: 39153508. doi:10.1016/j.radonc.2024.110477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。